Patents by Inventor Jorn Drappa

Jorn Drappa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD40L ANTAGONIST AND USES THEREOF IN THE TREATMENT OF LUPUS NEPHRITIS
    Publication number: 20240084024
    Abstract: A human CD40L-specific Tn3 molecule and therapeutic uses thereof for the treatment of lupus nephritis are provided herein. Also provided are therapeutic regimens that comprise a CD40L-specific Tn3 scaffold.
    Type: Application
    Filed: November 15, 2023
    Publication date: March 14, 2024
    Inventors: Gabor G. ILLEI, Ilias ALEVIZOS, Jorn DRAPPA, William A. REES
  • METHODS OF TREATING IMMUNE MEDIATED PULMONARY INJURY
    Publication number: 20230151093
    Abstract: The present disclosure relates to methods for treating or preventing immune-mediated pulmonary injury (IMPI) in a subject in need thereof, the method comprising administering to the subject an anti-Type I interferon (anti-T1i) therapy that blocks the activity, function or production of Type I interferon (T1i) in the subject, wherein the anti-T1i therapy is administered to the subject infected with a respiratory virus that causes a delayed T1i response in the subject.
    Type: Application
    Filed: September 30, 2022
    Publication date: May 18, 2023
    Inventors: Gabor ILLEI, William Rees, Jorn Drappa
  • METHODS OF TREATMENT USING ILT7 BINDING PROTEINS
    Publication number: 20220403020
    Abstract: The present disclosure is related to methods of treating autoimmune disorders in a subject comprising administering immunoglobulin-like transcript 7 (ILT7) binding proteins to a subject having elevated type I interferon gene signature (IFNGS). The present disclosure also relates to methods of reducing pDCs in tissues comprising administering an ILT7-binding protein to a subject in need thereof.
    Type: Application
    Filed: June 3, 2022
    Publication date: December 22, 2022
    Inventors: William REES, John N. RATCHFORD, Jodi KARNELL, Jorn DRAPPA, Gabor ILLEI
  • USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE
    Publication number: 20220204617
    Abstract: Methods for using an anti-CD19 antibody to treat autoimmune disease are disclosed herein. In particular the use of VIB551, a humanised, affinity-optimised, afucosylated IgG1 kappa monoclonal antibody to treat Neuromyelitis optica spectrum disorder.
    Type: Application
    Filed: April 23, 2020
    Publication date: June 30, 2022
    Inventors: Eliezer KATZ, Jorn DRAPPA, Kathleen MCKEEVER
  • CD40L ANTAGONIST AND USES THEREOF
    Publication number: 20210340200
    Abstract: A human CD40L-specific Tn3 molecule and therapeutic uses thereof.
    Type: Application
    Filed: September 25, 2019
    Publication date: November 4, 2021
    Inventors: Jorn DRAPPA, Marius ALBULESCU, Jing LI, Ethan GRANT, Katie STREICHER, Gabor ILLEI, Liangwei WANG, William REES
  • COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES
    Publication number: 20140056889
    Abstract: The invention provides methods and compositions for treating various autoimmune diseases (such as systemic lupus erythematousu) with an interferon inhibitor (such as an anti-intereron-alpha monoclonal antibody). More specifically, the invention provides a method of diagnosing, monitoring and adjusting the treatment of such a patient by way of an interferon signature metric (interferon response gene measurement value), a certain anti-dsDNA antibody titre or being ENA? (levels of extractable nuclear antigens lower than a healthy level). Furthermore, the invention provides articles of manufacture associated with such a diagnosis.
    Type: Application
    Filed: April 26, 2012
    Publication date: February 27, 2014
    Applicant: Genentech, Inc.
    Inventors: Alyssa M. Morimoto, Jacqueline McBride, Richard Boismenu, Romeo Maciuca, William D. Kennedy, Michael J. Townsend, Jorn Drappa